Human KIR2DL5 / CD158f Protein, Fc Tag
分子別名(Synonym)
KIR2DL5,CD158f
表達區(qū)間及表達系統(tǒng)(Source)
Human KIR2DL5 / CD158f Protein, Fc Tag (KIA-H5255) is expressed from human 293 cells (HEK293). It contains AA His 22 - His 240 (Accession # Q8N109-1).
Predicted N-terminus: His 22
蛋白結(jié)構(gòu)(Molecular Characterization)

This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 50 kDa. The protein migrates as 63-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in 50 mM Tris,100 mM Glycine,25 mM Arg,150 mM NaCl,pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

背景(Background)
殺傷細胞免疫球蛋白樣受體2DL5(KIR2DL5)屬于免疫球蛋白超家族,是NK細胞的抑制性受體。KIR2DL5由兩個同源基因編碼,這兩個基因顯示拷貝數(shù)變異和等位基因多態(tài)性——KIR2DL5A和KIR2DL5B,其結(jié)構(gòu)域僅變化2個氨基酸,信號肽僅變化1個氨基酸。KIR2DL5和KIR2DL4形成一個亞家族,其細胞質(zhì)尾部比其他KIR更長,每個都有一個D0和一個D2型Ig樣結(jié)構(gòu)域。
關(guān)鍵字: KIR2DL5;KIR2DL5蛋白;KIR2DL5重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。